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A panel of sulfated oligosaccharides was tested for antimalarial activity and inhibition of adhesion to the
placental malaria receptor chondroitin-4-sulfate (CSA). The heparan sulfate mimetic PI-88, currently under-
going phase II anticancer trials, displayed the greatest in vitro antimalarial activity against Plasmodium
falciparum (50% inhibitory concentration of 7.4 M) and demonstrated modest adhesion inhibition to cell
surface CSA.
Some of the severe pathophysiological symptoms of Plasmo-
dium falciparum infection, the causative agent of the most
lethal form of human malaria, involve carbohydrate interac-
tions. For example, infected erythrocytes (IEs) can adhere to
the glycosaminoglycans chondroitin-4-sulfate (CSA) and hyal-
uronic acid (6, 7, 14) in the placenta during pregnancy, and
heparan sulfate may be involved in the formation of P. falcipa-
rum rosettes (5, 9, 10). Negatively charged polysaccharides, such
as heparin, CSA, dextran sulfates, cellulose sulfates, fucoidan,
and the nonsulfated glycosaminoglycan hyaluronic acid, have
been shown experimentally to inhibit the in vitro invasion of P.
falciparum merozoites into erythrocytes, block cytoadhesion of
IEs to various host receptors (3, 11, 26), or disrupt P. falcipa-
rum rosettes (8, 24). In this study, we have examined a panel of
sulfated oligosaccharides, including the heparan sulfate mi-
metic PI-88 (17), which is currently undergoing phase II clin-
ical trials as an anticancer agent, both for their in vitro anti-
malarial activities and for their effects on adhesion to the host
receptor CSA.
A series of hypersulfated oligosaccharides (di- to hexasac-
charide, varying in sugar unit, linkage between sugars, and
structure of the reducing terminus sugar) were used (Sigma,
MO) (Table 1) (20). Each of the prepared sulfated oligo-
saccharides, along with dextran sulfate (5 kDa) and PI-88
(average molecular mass of 2.4 kDa; composed predomi-
nately of penta- and tetrasaccharides), possesses between three
and five hydroxyl groups per saccharide unit available for sul-
fation, while pentosan polysulfate (5 kDa) has two. The in vitro
antimalarial activities of this panel of sulfated saccharides were
examined using the multidrug-resistant P. falciparum clone
Dd2 and [3H]hypoxanthine incorporation, as previously de-
scribed (4, 13). Early-ring-stage IEs were incubated with vari-
ous concentrations of each substance for 48 h before adding
[3H]hypoxanthine and culturing for a further 24 h. All of the
sulfated saccharides used in this work displayed similar anti-
malarial 50% inhibitory concentration values, with the larger
oligosaccharides, maltopentaose sulfate and maltohexaose
sulfate, being more potent than the smaller oligosaccharides
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TABLE 1. Effects of sulfated saccharides on P. falciparum in vitro









PI-88 7.4 (10) 87.6 (10.5)
Dextran sulfate (5 kDa) NT 82.8 (7.4)
Pentosan polysulfate (5 kDa) NT 86.1 (0.2)
Maltose sulfate 26.7 (4) 29.6 (9.0)
Maltotriose sulfate 20.3 (5) 19.7 (9.9)
Maltotetraose sulfate 31.5 (2) 18.9 (5.2)
Maltopentaose sulfate 13.3 (5) 70.7 (16.5)
Maltohexaose sulfate 13.2 (7) 76.6 (52.3)
Isomaltotriose sulfate 35.0 (10) 42.4 (4.4)
Maltitol sulfate 36.3 (10) 28.3 (13.5)
Maltotriitol sulfate 25.8 (21) 51.3 (14.7)
Panose sulfate NT 42.7 (3.5)
Lactitol sulfate 23.3 (7) 39.3 (5.9)
a Average 50% inhibitory concentration values (IC50) (standard deviations)
for at least two independent experiments, each carried out in triplicate, are
shown. NT, not tested.
b Percentages of inhibition (standard deviations) compared to that for un-













(Table 1). The antimalarial activities obtained for these oligo-
saccharides are similar to those previously observed for a range
of sulfated polysaccharides (1, 3, 11, 26), suggesting promiscu-
ous inhibition by any sulfated polyanion. The most effective
compound was PI-88, which gave an antimalarial 50% inhibi-
tory concentration of 7.4 M (Table 1) and a 90% inhibitory
concentration of 13.9 M. These values are similar to the mean
values of maximum concentration of drug in plasma (8.4 to
12.5 M) which are achieved in cynomolgus monkeys following
subcutaneous or intravenous administration of a single dose of
PI-88 at 10 mg/kg of body weight (12). Given the extensive
work already carried out on the clinical use of PI-88, this
compound was more thoroughly studied for its stage-specific
activity against malaria. PI-88 did not effect maturation of Dd2
ring-stage parasites to trophozoites (Fig. 1A) but was found to
interfere with the invasion of P. falciparum merozoites into
new erythrocytes (Fig. 1B). Whether this is due to an effect on
schizont rupture or a direct effect on merozoite entry into new
erythrocytes remains to be determined. Similar results were
obtained for the drug-sensitive P. falciparum line 3D7 (not
shown). At this stage, it is not known if the mechanism of
action of PI-88 is due to a specific interaction with a P. falcipa-
rum molecule or is a nonspecific effect of the high net negative
charge of PI-88.
We next tested the effect of the sulfated saccharides in vitro
on CSA-specific adhesion of P. falciparum IEs. P. falciparum
clone 3D7 IEs that had been selected more than eight times on
CHO-K1 cells for a CSA-binding phenotype (3D7csa) (3) were
preincubated with 100 g/ml of saccharide prior to adhesion to
CHO-K1 cells. IEs were exposed to cell monolayers (70 to 90%
confluence) for 1 h, with gentle agitation every 15 min, before
washing away unbound erythrocytes, fixing with 2% glutaral-
dehyde (Sigma), and staining with Giemsa. CSA-specific ad-
hesion was determined by measuring displacement with 100
g/ml of soluble CSA (Sigma). The sulfated disaccharides malt-
ose sulfate, maltitol sulfate, and lactitol sulfate were poorer
inhibitors than the longer-chain molecules, with PI-88, malto-
pentaose sulfate, and maltohexaose sulfate being the most
potent (Table 1). Again, PI-88 was examined more extensively
for its effect on P. falciparum cytoadhesion. The effect of PI-88
on CSA-specific adhesion of 3D7csa IEs to CHO-K1 cells was
tested over a range of concentrations; however, significant
inhibition was obtained only at 100 g/ml and, to a lesser
extent, at 10 g/ml (P  0.009 and 0.086, respectively; two-
tailed Student’s t test) (Fig. 2). Soluble CSA (100 g/ml) in-
hibited binding by more than 90%, confirming CSA-specific
binding to CHO-K1 cells (not shown). We next investigated
whether PI-88 was able to effect adhesion to the common P.
falciparum host receptor CD36. Adhesion to CD36 has re-
cently been associated with nonsevere disease (2, 22) and may
afford protection via sequestration of IEs in nonvital sites such
as the skin and muscle (2, 25). Thus, interfering with CD36
adhesion may promote adhesion to other parasite receptors,
such as ICAM-1, which may in turn lead to more-severe dis-
ease outcomes, such as cerebral malaria (19). When the effect
of PI-88 on CD36-specific adhesion of 3D7 P. falciparum IEs to
FIG. 1. Stage-specific effects of PI-88 on in vitro development of P. falciparum IEs. P. falciparum Dd2 IEs were treated with either 100 g/ml
(gray bars) or 50 g/ml (striped bars) PI-88 or left untreated (black bars) starting at either ring stage (A, 26-h treatment) or trophozoite stage (B,
19-h treatment). Percent parasitemia was determined by microscopic examination of Giemsa-stained thin smears. Representative experiments are
shown.
FIG. 2. Effect of PI-88 on CSA- and CD36-specific adhesion of P.
falciparum IEs. CSA-binding (3D7 selected on CHO-K1 cells [3D7csa])
or CD36-binding (unselected 3D7) P. falciparum IEs were preincu-
bated with various concentrations of PI-88 prior to adhesion to
CHO-K1 (black bars) or C32 (gray bars) cells, respectively. CSA-
specific adhesion was determined by the addition of 100 g/ml soluble
CSA, whereas CD36-specific adhesion was determined using 5 g/ml
of the anti-CD36 monoclonal antibody FA6/152. The average percent-
ages of binding (standard deviations) compared to that for untreated
controls for three independent experiments are shown.












C32 melanoma cells was examined (Fig. 2), the inhibition ob-
tained was not significantly different from that obtained with
controls (P  0.1; two-tailed Student’s t test). An anti-CD36
monoclonal antibody was used as a control for CD36 specificity
and, as expected, completely inhibited adhesion of P. falcipa-
rum IEs to C32 cells (not shown).
Until recently, the only sulfated oligosaccharide to be used
clinically against human malaria was heparin (18, 21), which
has been discontinued due to heparin-induced hemorrhagic
complications. Recently, preclinical and clinical studies have
shown that curdlan sulfate, which has a 10-fold-lower anti-
coagulant activity than heparin, may reduce disease severity in
patients with severe and severe/cerebral malaria, although
sample sizes in these studies were small (15). PI-88 is a mimetic
of heparan sulfate, yet it possesses decreased anticoagulant
properties compared with heparin and may therefore be more
favorable as an adjunct therapy due to decreased risk of hem-
orrhagic complications. This oligosaccharide does, however,
have limitations; phase I studies indicated that intravenous
administration at 2.28 mg/kg/day for 2 weeks resulted in im-
mune-mediated thrombocytopenia in some patients (23), and a
short half-life of approximately 1 h has been measured in rats
(16), although improvements in pharmacokinetic properties of
sulfated oligosaccharides of this type are possible (16). These
issues, together with the likelihood that such compounds
would be effective only with parenteral administration, will
need to be addressed if such a carbohydrate-based drug is to be
developed as a novel antimalarial therapy.
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